Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
TLT.Vthis companyTheralase Technologies Inc.	CA$0.19	-10.12×	23.49×	51.16×	-10.75×	-125.9%	29.6%	-511.4%	-504.7%	-231.8%	-186.7%	-8.0%	0.26×	-0.07×	-99.25×	1.25×	0.0%	2	14.98	1	C-
ARCH.VArch Biopartners Inc.	CA$0.89	-54.01×	-21.63×	0×	-67.06×	-107.1%	0.0%	0.0%	0.0%	40.0%	145.7%	-1.9%	-0.73×	-2.19×	-5.88×	0.03×	0.0%	2	-1,107.49	2	C
BCT.TOBriaCell Therapeutics Corp.	CA$5.51	-0.68×	1.47×	0×	-0.39×	-83.3%	0.0%	0.0%	0.0%	-216.0%	-234.6%	-120.9%	0×	0.27×	0×	2.76×	0.0%	1	-10.15	2	C
BETR.CNBetterLife Pharma Inc.	CA$0.22	-4.9×	-0.75×	0×	-4.53×	-113.2%	0.0%	0.0%	0.0%	15.3%	32.4%	-8.6%	-0.09×	-0.49×	-7.8×	0.03×	0.0%	3	-83.43	2	C
DTC.CNDefence Therapeutics Inc.	CA$0.36	-4×	7.79×	0×	-5.53×	-98.2%	0.0%	0.0%	0.0%	-190.7%	-94.2%	-17.4%	0.49×	0.03×	-12.15×	3.42×	0.0%	2	-5.63	1	C-
EPRX.TOEupraxia Pharmaceuticals Inc.	CA$10.34	-9.83×	5.04×	0×	-8.54×	-78.4%	0.0%	0.0%	0.0%	-47.9%	-48.6%	-7.2%	0×	2.07×	0×	15.12×	0.0%	2	34.16	2	C
Peer median	—	-4.9×	1.47×	0×	-5.53×	-98.2%	0.0%	0.0%	0.0%	-47.9%	-48.6%	-8.6%	0×	0.03×	-5.88×	2.76×	0.0%	2	-10.15	2	—